Opinion|Videos|January 20, 2025
University of Kansas Medical Center Insights: CAR T Referral Process
Panelists discuss how the chimeric antigen receptor T-cell referral pathway progresses from initial community physician contact through patient evaluation and final selection, highlighting the key steps and considerations in the institutional workflow process.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Walk us through the typical chimeric antigen receptor T-cell referral process at your institution, from the initial community physician outreach to the patient evaluation and selection.
Advertisement
Related to this article
An end-of-phase 2 meeting with the FDA supports a phase 3 development program for silevertinib in patients with locally advanced or metastatic NSCLC.
The FDA issued a Not Approvable Letter due to uncertainty around the degree of clinical benefit with Optune Mya for patients with NSCLC and brain metastases.
Ryosuke Tateishi, MD, PhD, discussed lifestyle interventions, surveillance, and what the US and Japan can share to prevent MASLD-related liver cancer.
Israel approved nogapendekin alfa inbakicept plus BCG for BCG-unresponsive NMIBC with CIS, expanding access beyond the US, UK, EU, Saudi Arabia, and UAE.
At The Liver Meeting 2026, Ryosuke Tateishi, MD, PhD, discussed what the US and Japan can learn from each other to prevent liver cancer.
Posters at The Liver Meeting 2026 refined HCC risk stratification in hepatitis delta or after HCV cure and examined ICI liver injury in cirrhosis.
A dual bispecific regimen of pasritamig and JNJ-9401 reduced PSA by at least 50% in 73% of heavily pretreated patients with metastatic CRPC.
In pooled phase 1/2 data, the PD-1/VEGF bispecific antibody cesalatamig produced a 33% objective response rate in PD-(L)1–resistant/refractory NSCLC.
Advertisement
Advertisement
Trending on CancerNetwork
1
Pasritamig Plus JNJ-9401 Yields 73% PSA Response in Metastatic CRPC
2
Nogapendekin Alfa/BCG Earns Israeli Approval in BCG-Unresponsive NMIBC
3
Cesalatamig Monotherapy Yields Responses in PD-(L)1–Resistant NSCLC
4
PIKTOR Plus Paclitaxel Yields Responses in Pretreated PAM-Mutated Endometrial Cancer
5